Exhaled Breath Olfactory Signature of Pulmonary Arterial Hypertension (SNOOPY2)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02782026 |
Recruitment Status : Unknown
Verified December 2016 by Assistance Publique - Hôpitaux de Paris.
Recruitment status was: Recruiting
First Posted : May 25, 2016
Last Update Posted : October 2, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
In this prospective case-control study, the investigators will evaluate the diagnostic performance of a novel electronic nose (E-nose) for the detection of Pulmonary Arterial Hypertension (PAH). This study is designed to:
- Assess the performance of the E-nose to discriminate controls from patients with PAH
- Assess the performance of the E-nose to discriminate between different subtypes of pulmonary hypertension (PH), namely idiopathic PAH, heritable PAH with BMPR2 mutation and chronic thromboembolic PH
- Assess the performance of the E-nose to discriminate controls from asymptomatic patients with PH who carry BMPR2 mutations.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pulmonary Hypertension | Device: Exhaled Breath Olfactory Signature (Artificial Nose) | Not Applicable |
Pulmonary arterial hypertension (PAH) is a progressive and rare severe disease (prevalence of 15-50 per million) due to obstruction of small pulmonary arteries, leading to an increase in pulmonary artery pressure with the ultimate consequence right heart failure. Despite recent advances in therapeutic care, there is no cure and most patients die or require lung transplantation within 5 years of diagnosis. Currently, right heart catheterisation is required to diagnose PAH and monitor response to treatment. Right heart catheterisation is an invasive test, and alternatives such as echocardiography have not yielded sufficient accuracy both for early diagnosis and disease monitoring. Currently, PAH is often diagnosed at an advanced stage of the disease. There is often a delay in diagnosis of several years between the first symptoms and the identification of the disease due to the non-specific nature of symptoms. Hence, there is the need to improve the time between the first signs and definitive diagnosis of the disease. Early diagnosis of PAH remains a challenge due to the low sensitivity and specificity of biomarkers available currently.
The main objective is to validate the results obtained in the previous preliminary proof of concept study - that PAH patients display a unique olfactory signature that can be detected by an artificial E- nose.
Secondary objectives are to investigate the ability of the E-nose to:
- Discriminate patients with idiopathic PAH from those with heritable PAH due to BMPR2 mutations
- Discriminate patients with chronic thromboembolic pulmonary hypertension (CTEPH) from healthy controls, and patients with idiopathic and/or heritable PAH.
- Detect development of PAH in BMPR2 mutation carriers
- Determine whether the olfactory signature can stratify subgroups of patients by correlating the olfactory signature to different biological and clinical parameters (hemodynamic measurements, NYHA class, duration of treatment, 6-minute walk distance, response to nitric oxide, BNP levels).
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 350 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | Exhaled Breath Olfactory Signature of Pulmonary Arterial Hypertension Detected by an Artificial Nose: A Clinical Validation Study |
Study Start Date : | March 2016 |
Estimated Primary Completion Date : | September 2018 |
Estimated Study Completion Date : | September 2018 |

Arm | Intervention/treatment |
---|---|
Experimental: idiopathic PAH
Exhaled Breath Olfactory Signature Detected by an Artificial Nose
|
Device: Exhaled Breath Olfactory Signature (Artificial Nose) |
Experimental: heritable PAH with BMPR2 mutation
Exhaled Breath Olfactory Signature Detected by an Artificial Nose
|
Device: Exhaled Breath Olfactory Signature (Artificial Nose) |
Experimental: chronic thromboembolic PH
Exhaled Breath Olfactory Signature Detected by an Artificial Nose
|
Device: Exhaled Breath Olfactory Signature (Artificial Nose) |
Experimental: Controls
Exhaled Breath Olfactory Signature Detected by an Artificial Nose
|
Device: Exhaled Breath Olfactory Signature (Artificial Nose) |
- Volatile organic compounds in exhaled breath in patients of each group detected using sensor array on the basis of cross-reactive gold-nanoparticles coated with organic ligands. [ Time Frame: Up to 4 hours ]The primary endpoint will be the ability of the E-nose to discriminate patients with PAH from healthy controls by their olfactory signature from the profile of volatile organic compounds in exhaled breath.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Patients group
- Age 18 to 65 years inclusive
- Idiopathic or heritable PAH confirmed by right heart catheterization
- Patients with CTEPH confirmed by right heart catheterization
Healthy control group:
- Age 18 to 65 years inclusive
- No known allergy
- No history of known pathology
- Not genetically linked with the patient
At risk group:
- Subjects included in the protocol Delphi2
Exclusion Criteria:
Patients group:
Any of the following:
- Connective tissue disease
- Infection with HIV
- Portal hypertension or liver disease
- Congenital Heart Disease
- Asthma and other coexisting lung disease
Healthy control group:
- Pregnant or breastfeeding woman
- Addiction to alcohol
- Tabacco addiction

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02782026
Contact: Marc Humbert, MD,PhD | +33 140942512 | marc.humbert@bct.aphp.fr |
France | |
AP-HP, Bicêtre Hospital | Recruiting |
Le Kremlin-Bicêtre, France, 94275 | |
Contact: Marc Humbert, MD, PhD +33 1 45217972 marc.humbert@bct.aphp.fr |
Principal Investigator: | Marc Humbert, MD,PhD | Assistance Publique - Hôpitaux de Paris |
Responsible Party: | Assistance Publique - Hôpitaux de Paris |
ClinicalTrials.gov Identifier: | NCT02782026 |
Other Study ID Numbers: |
2014-01321-46 |
First Posted: | May 25, 2016 Key Record Dates |
Last Update Posted: | October 2, 2017 |
Last Verified: | December 2016 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
pulmonary hypertension early detection |
Hypertension, Pulmonary Hypertension Vascular Diseases |
Cardiovascular Diseases Lung Diseases Respiratory Tract Diseases |